Metformin for Fibromyalgia Symptoms (INFORM Trial)
Status:
Active, not recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
The main purpose of the project is to evaluate the safety and efficacy of low dose metformin
for improving symptoms associated with fibromyalgia syndrome (FMS) via modulating
neuroinflammatory pathways. The investigators hypothesize that FMS patients in the low-dose
metformin conditions will show greater improvement in FMS symptoms than those who are in the
placebo group. Further, the investigators hypothesize that metformin will increase
phosphorylated AMPK in peripheral immune cells of FMS patients and will decrease the
transcription of mTORC1, NLRP3 inflammasome, and nociceptive cytokines interleukin 1beta and
interleukin 18.
Phase:
Phase 2
Details
Lead Sponsor:
University of Utah
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)